CytomX Therapeutics, Inc.

CytomX Therapeutics Misses on Revenue, Stock Down 4.45%

CytomX Therapeutics reported a narrower-than-expected loss per share, which was a positive surprise. However, the stock fell by 4.45% in reaction, indicating that investors may have been disappointed by the lack of revenue information and guidance. The absence of management commentary leaves uncertainty about future performance.